


**In the Claims**

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 14-15 and amend pending claims 16, 18-26 and 35-36 as noted below.


1-15. (Canceled)

16. (Currently amended) A pharmaceutical preparation comprising a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising ~~The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises~~




wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;  
wherein Y is selected from the group consisting of rhamnose and H; and  
wherein Z is selected from the group consisting of glucose and H; and  
a pharmaceutically acceptable carrier.

17. (Original) The pharmaceutical preparation of claim 14 16 wherein the polysaccharide comprises




18. (Currently amended) A pharmaceutical preparation comprising a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising ~~The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises~~




wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;  
wherein Y is selected from the group consisting of rhamnose and H; and  
wherein Z is selected from the group consisting of glucose and H; and  
a pharmaceutically acceptable carrier.

19. (Currently amended) A pharmaceutical preparation comprising a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising ~~The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises~~



wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;  
wherein Y is selected from the group consisting of rhamnose and H; and  
wherein Z is selected from the group consisting of glucose and H; and  
a pharmaceutically acceptable carrier.

20. (Currently amended) A pharmaceutical preparation comprising a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising ~~The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises~~



wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;  
wherein Y is selected from the group consisting of rhamnose and H; and  
wherein Z is selected from the group consisting of glucose and H; and  
a pharmaceutically acceptable carrier.

21. (Currently amended) The pharmaceutical preparation of claim 14 16 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.


22. (Currently amended) The pharmaceutical preparation of claim 14 16 wherein the pharmaceutical preparation is sterile.

23. (Currently amended) The pharmaceutical preparation of claim 14 16 wherein the pharmaceutical preparation is formulated in a unit dosage in an amount effective for treating *Pseudomonal* infection.

24. (Currently amended) The pharmaceutical preparation of claim 14 16 wherein the pharmaceutical preparation is formulated as an aerosol for inhalation.


25. (Currently amended) The pharmaceutical preparation of claim 14 16 wherein the pharmaceutical preparation is formulated as an injectable preparation.

26. (Currently amended) A composition of matter comprising  
a covalent conjugate of a non-toxic lipid for associating a bioactive agent with  
a polysaccharide, wherein the non-toxic lipid is not lipid A and a polysaccharide comprising




wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.


27. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises




28. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises




29. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises




30. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



31. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



32. (Previously Presented) The composition of matter of claim 26 wherein the polysaccharide comprises




33. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

34. (Previously Presented) The composition of matter of claim 26 wherein the lipid has the following structural formula:  $\text{CH}_3(\text{CH}_2)_n\text{COOH}$  wherein  $n=1-50$ .


35. (Currently amended) The composition of matter of claim 34 wherein the lipid is in the wall of a liposome containing a bioactive agent, ~~wherein the bioactive agent is selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of a cell, an anti-microbial molecule and a therapeutic molecule.~~

36. (Currently amended) A composition of matter comprising  
a covalent conjugate of a bioactive agent wherein the bioactive agent is not lipid A ~~selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of a cell, an anti-microbial molecule and a therapeutic molecule,~~ and a polysaccharide comprising




wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.

37. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises




38. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises




39. (Original) The composition of matter of claim 36 wherein the polysaccharide


comprises





40. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



41. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



42. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



43. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

Serial No.: 09/405,735  
Conf. No.: 9816

- 9 -

Art Unit: 1637

44-68. (Canceled)